These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 22567063)

  • 1. On the proper use of the crossover design in clinical trials: part 18 of a series on evaluation of scientific publications.
    Wellek S; Blettner M
    Dtsch Arztebl Int; 2012 Apr; 109(15):276-81. PubMed ID: 22567063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishing equivalence or non-inferiority in clinical trials: part 20 of a series on evaluation of scientific publications.
    Wellek S; Blettner M
    Dtsch Arztebl Int; 2012 Oct; 109(41):674-9. PubMed ID: 23264808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carryover negligibility and relevance in bioequivalence studies.
    Ocaña J; Sanchez O MP; Carrasco JL
    Pharm Stat; 2015; 14(5):400-8. PubMed ID: 26175204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease.
    Putt ME; Ravina B
    Control Clin Trials; 2002 Apr; 23(2):111-26. PubMed ID: 11943439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crossover trials with a binary response: a powerful method despite the carryover effect.
    Cleophas TJ; van Lier HJ
    J Clin Pharmacol; 1996 Mar; 36(3):198-202. PubMed ID: 8690812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal and efficient crossover designs under different assumptions about the carryover effects.
    Hedayat AS; Stufken J
    J Biopharm Stat; 2003 Aug; 13(3):519-28. PubMed ID: 12921398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian analysis of the two-period crossover design for clinical trials.
    Grieve AP
    Biometrics; 1985 Dec; 41(4):979-90. PubMed ID: 3830262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal and/or Efficient Two treatment Crossover Designs for Five Carryover Models.
    Gondaliya J; Divecha J
    Int J Biostat; 2018 Nov; 14(2):. PubMed ID: 30471221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Handling of baseline measurements in the analysis of crossover trials.
    Chen X; Meng Z; Zhang J
    Stat Med; 2012 Jul; 31(17):1791-803. PubMed ID: 22715129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cluster-crossover design: a method for limiting clusters level effect in community-intervention studies.
    Parienti JJ; Kuss O
    Contemp Clin Trials; 2007 May; 28(3):316-23. PubMed ID: 17110172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis of crossover trials for absorbing binary endpoints.
    Nason M; Follmann D
    Biometrics; 2010 Sep; 66(3):958-65. PubMed ID: 19930189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carryover and the two-period crossover clinical trial.
    Willan AR; Pater JL
    Biometrics; 1986 Sep; 42(3):593-9. PubMed ID: 3567292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crossover Designs in Nutrition and Dietetics Research.
    Harris JE; Raynor HA
    J Acad Nutr Diet; 2017 Jul; 117(7):1023-1030. PubMed ID: 28479137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the crossover design in the presence of residual effects.
    Lehmacher W
    Stat Med; 1991 Jun; 10(6):891-9. PubMed ID: 1876779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of two-treatment, two-period crossover trials in emergency medicine.
    Reed JF
    Ann Emerg Med; 2004 Jan; 43(1):54-8. PubMed ID: 14707941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Crossover designs in lower extremity wounds.
    Reed JF
    Int J Low Extrem Wounds; 2003 Sep; 2(3):158-63. PubMed ID: 15866840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A critique of recent research on the two-treatment crossover design.
    Fleiss JL
    Control Clin Trials; 1989 Sep; 10(3):237-43. PubMed ID: 2676339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.